The NHS has expanded access to the RSV vaccine in England, making millions more older adults eligible as health officials aim to reduce seasonal pressure on hospitals caused by respiratory infections.
From April 2026, all adults aged 80 and over, as well as residents in care homes for older people, can receive the RSV vaccine.
The policy shift significantly broadens the programme, which previously targeted individuals aged 75 to 79 and those turning 75 since its launch in 2024.
Michelle Kane, NHS Director of Vaccination and Screening Delivery, urges those eligible to get the vaccine as soon as possible: “Respiratory syncytial virus (RSV) is not just a winter illness; it can occur all year round and can make older people seriously ill, so it is vital everyone eligible gets vaccinated.
“The vaccine has been proven to drastically reduce the chance of those aged 75 and over from ending up in hospital with an RSV infection, so if you’re seeing loved ones or family members who are eligible for a vaccine over the Easter break, please do remind them to come forward if invited.
“If you are newly eligible or are yet to come forward, don’t delay and book your free NHS vaccination with your GP or speak to a member of staff in your care home. It could prevent you from developing a severe illness like pneumonia and even save your life”.
Rising concern over RSV in ageing populations
RSV is a widespread respiratory pathogen that typically causes mild, cold-like symptoms.
However, in older adults – particularly those with underlying health conditions – it can lead to severe complications, including pneumonia, bronchitis, and exacerbations of chronic lung disease.
These complications often require hospital care. In the UK, RSV is associated with approximately 9,000 hospital admissions annually among people aged over 75, according to health data.
Clinicians note that the virus can significantly impair breathing in vulnerable patients, increasing both morbidity and healthcare demand during peak seasons.
Vaccination strategy and expected impact
Health authorities expect the expanded RSV vaccine programme to help reduce these admissions by offering longer-term protection through a single dose, which evidence suggests remains effective for several years.
The decision to widen eligibility reflects both demographic trends and healthcare system pressures, particularly during winter months when respiratory illnesses surge. By targeting those at highest risk, policymakers aim to mitigate avoidable hospitalisations and improve outcomes in older populations.
How to get the RSV vaccine
Eligible individuals can arrange vaccination through their GP practices. In addition, care home staff are facilitating access for residents, and selected community pharmacies in parts of England are participating in the rollout.
The NHS has also maintained eligibility for earlier priority groups. Adults aged 75 to 79 who have not yet been vaccinated remain eligible, as do individuals turning 75.
Pregnant women continue to be offered the RSV vaccine from 28 weeks’ gestation to protect newborns from severe respiratory infections in early life.
Broader implications for public health
The expansion of the RSV vaccine programme underscores a growing focus on preventative strategies in ageing populations.
With RSV contributing substantially to winter healthcare pressures, increasing vaccine uptake among high-risk groups could play a measurable role in easing system strain while improving patient outcomes.
Team Health Accessible
Health & Wellness Editorial Team
HealthAccessible editorial team delivers trusted, accessible, and evidence-based health information for everyone.
